Search
Mipicoledine
go.drugbank.com/drugs/DB15075InvestigationalMipicoledine is under investigation in clinical trial NCT01048008 (Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer).
Synonyms: DM-CHOC-PENMoxidectin
go.drugbank.com/drugs/DB11431ApprovedInvestigationalVet approvedMoxidectin differs by the absence of a disaccharide moiety on carbon 13, a substituted olefinic side chain at carbon 25 and a unique methoxime moiety at carbon 23. … It is a semi-synthetic methoxine derivative of nemadectin which is a 16-member pentacyclic lactone of the milbemycin class.
Categories: Compounds used in a research, industrial, or household settingSebelipase alfa
go.drugbank.com/drugs/DB11563ApprovedInvestigational[L39337] Sebelipase alfa is a recombinant form LAL approved for the treatment of LAL deficiency. … It was first approved by both the FDA and EMA in 2015 and is marketed under the brand name Kanuma (Alexion Pharmaceuticals).[L39337,L39342]
Human Rho(D) immune globulin
go.drugbank.com/drugs/DB11597ApprovedRho (D) immune globulin is available as a sterile, lyophilized or liquid gamma globulin (IgG) fraction containing antibodies to the Rh0 (D) antigen (D antigen) under the name Rhophylac (IM/IV). … Immune globullin was purified via ion-exchange chromatography method and prepared from pools of human plasma, where the donors are Rho (D)-negative donors who have been immunized with Rho(D)-positive RBCs
Categories: anti-D (rh) immunoglobulinSynonyms: IGG, Rho (D), Anti-D immunoglobulinDarolutamide
go.drugbank.com/drugs/DB12941ApprovedInvestigationalDarolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). … [A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019.[L10887]
Siltuximab
go.drugbank.com/drugs/DB09036ApprovedInvestigationalSiltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. … It is administered as a 1 hour intravenous infusion every 3 weeks.
Zilganersen
go.drugbank.com/drugs/DB18161ApprovedInvestigationalZilganersen is a glial fibrillary acidic protein (GFAP)-directed antisense oligonucleotide used to treat Alexander disease. … [L64096] The FDA approved zilganersen on September 3, 2026 for the treatment of Alexander disease in pediatric and adult patients, making it the first and only disease-modifying treatment for the condition
Pegulicianine
go.drugbank.com/drugs/DB18731ApprovedInvestigationalPegulicianine itself is a prodrug comprising three main fragments, one of which contains a fluorescence quencher that keeps the parent molecule optically inactive. … [L50537] The _in vivo_ enzymatic cleavage of pegulicianine results in two optically active fragments that emit a fluorescent signal that can be detected using a fluorescence imaging device.
Categories: Compounds used in a research, industrial, or household settingDrotaverine
go.drugbank.com/drugs/DB06751ApprovedWithdrawn[A231619] Drotaverine is not approved by the FDA, European Medicines Agency, or Health Canada. It is approved for use in Thailand as oral tablets or intramuscular injections.[L22689] … [A231619] It is a benzylisoquinoline derivative that is structurally related to [papaverine], although it displays more potent antispasmodic activities than papaverine.
Tedizolid phosphate
go.drugbank.com/drugs/DB09042ApprovedThis product is currently available as both an oral tablet and as a powder for intravenous injection.[L11232] … [L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®).
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates